Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of SH T 586 in Combination With Rituximab to Treat Low-Grade NHL

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with CD 20 positive, relapsed/refractory indolent lymphoma. (Regimens of prior chemotherapy are limited to 2; prior rituximab treatments up to 16 times are allowed.)~* Patients with measurable lesions (\> 1.5 cm).~* Patients who have not received any treatment for more than 4 weeks after completing previous therapies (6 months in the case of antibody therapies).~* ECOG performance status: 0 - 1~* Patients with adequately maintained organ functions.~Exclusion Criteria:~* Patients with infectious disease, serious complications, serious gastrointestinal symptoms, serious bleeding tendency, serious CNS symptoms, fever \</=38 °C, interstitial pneumonia or pulmonary fibrosis, active other malignancies, autoimmune hemolytic anemia or the history of the disease, or glaucoma.~* Patients who are positive for HBs antigen, HCV antibody, or HIV antibody.~* Patients who received G-CSF or transfusion within 1 week before the registration.~* Patients with the history of allergies to purine nucleoside analogue.~* Patients who experienced serious hypersensitivity or anaphylaxis to rituximab or mouse protein-derived products.~* Patients who had ever received prior therapy with fludarabine phosphate injection, pentostatin, cladribine, SH T 586, blood stem cell transplant, or monoclonal antibody therapy other than rituximab to NHL (including radioimmunotherapy).~* Patients who had progressive disease within 6 months of receiving therapy including rituximab.~* Women who are pregnant, of childbearing potential, or lactating.~* Patients who do not agree to practice contraception.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None
- Arm 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).